Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Share-based Compensation (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Share-based Compensation for 15 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 132.45% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.1 million through Dec 2025, up 65.95% year-over-year, with the annual reading at $6.1 million for FY2025, 65.95% up from the prior year.
  • Share-based Compensation for Q4 2025 was $1.7 million at Niagen Bioscience, roughly flat from $1.8 million in the prior quarter.
  • The five-year high for Share-based Compensation was $1.9 million in Q1 2022, with the low at $735000.0 in Q3 2024.
  • Average Share-based Compensation over 5 years is $1.3 million, with a median of $1.3 million recorded in 2021.
  • The sharpest move saw Share-based Compensation tumbled 34.2% in 2024, then skyrocketed 138.91% in 2025.
  • Over 5 years, Share-based Compensation stood at $1.5 million in 2021, then fell by 9.98% to $1.3 million in 2022, then decreased by 21.79% to $1.0 million in 2023, then dropped by 27.48% to $752000.0 in 2024, then skyrocketed by 132.45% to $1.7 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $1.7 million, $1.8 million, and $1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.